Shareholders meeting

5th September, 2026 To, To, The General Manager The Manager, Department of Corporate Services Listing Department, BSE Ltd. National Stock Exchange of India Ltd. Phiroze Jeejeebhoy Towers, “Exchange Plaza”, C-1, Block G, Dalal Street, Bandra-Kurla Complex, Mumbai – 400 001. Bandra (E), Mumbai – 400 051. Ref.: Scrip Code No. : 540701 (Equity) Ref. : (i) Symbol – DCAL : 975834, 976560, 977467, 977859 and (ii) Series – EQ 978062 (Debt) SUB.: SUBMISSION OF NOTICE OF 19TH ANNUAL GENERAL MEETING ALONGWITH ANNUAL REPORT FOR THE FINANCIAL YEAR 2025-26 AS PER REGULATIONS 34 AND 53 OF SEBI (LODR) REGULATIONS, 2015 Dear Sir, With reference to the captioned subject, please find enclosed herewith the copy of Notice of 19th Annual General Meeting (“AGM”) of the Company scheduled to be held on Wednesday, the 30th September, 2026 at IST 15:00 hrs. through Video Conferencing (“VC”) or Other Audio Visual Means (“OAVM”), in accordance with relevant circulars issued by Ministry of Corporate Affairs and Securities and Exchange Board of India ("Circulars") alongwith the Annual Report for the financial year 2025- 26. The said Annual Report also contains the Corporate Governance Report, Management Discussion & Analysis Report, Business Responsibility and Sustainability Report as per the relevant provisions of the Companies Act, 2013 and SEBI (LODR) Regulation, 2015. Pursuant to the provisions of Section 108 of the Companies Act, 2013 and Rule 20 of the Companies (Management and Administration) Rules, 2015 read with Regulation 44 of SEBI (LODR) Regulations, 2015 and Circulars, the shareholders of the Company are being provided the facility for voting through remote e-voting, for participation in the AGM through VC/OAVM facility and e-Voting during the AGM through CDSL e- Voting platform. The procedure for participating/joining in the meeting through VC/OAVM and e-Voting are provided in Notice of AGM. The e-Voting period commence on, Sunday, 27th September, 2026 at 9.00 a.m. and ends on Tuesday, 29th September, 2026 at 5.00 p.m. During this period, shareholders holding shares either in physical form or in dematerialised mode as on Wednesday, 23rd September, 2026 (cut-off date) may cast their vote electronically. Notice of the 19th AGM alongwith the Annual Report for the financial year 2025-26 is also available on the Company’s website: www.imdcal.com. Kindly take this on your record. Thanking you. Yours faithfully, For, Dishman Carbogen Amcis Limited Shrima Dave Company Secretary Encl.: As above Global Science. Unified Execution. Dishman Carbogen Amcis Limited Annual Report 2025-26 Inside this report pg.04 pg.64 Strategic Review CORPORATE OVERVIEW 06 About Us 10 Our Global Presence 64 Statutory 12 Portfolio Offerings Reports 16 Distinct Capabilities of imdcal 66 Management Discussion and Analysis 18 Segment-wise Performance 86 Corporate Information 20 Key Performance Indicators 88 Notice 22 Message from the Global Managing Director 102 Directors’ Report 126 Business Responsibility & Sustainability Report (BRSR) pg.24 156 Corporate Governance Report pg.46 Financial Statements 24 Strategic Review 190 Standalone Financial Statement OUR EVOLVING CAPABILITIES 263 Consolidated Financial Statement 26 Manufacturing Facilities 36 R&D Capabilities 40 Digital Infrastructure 44 Sustained Value Creation Model Safe Harbour Statement This document contains statements that the assumptions, predictions, and statements. Accordingly, this 46 Strategic Review about expected future events, financial other forward-looking statements will document is subject to the disclaimer and operating results of Dishman not prove to be accurate. Readers are and qualified in its entirety by OUR ESG COMMITMENT Carbogen Amcis Limited, which are cautioned not to place undue reliance the assumptions, qualifications forward-looking. By their nature, on forward- looking statements as and risk factors referred to in the 48 Environmental Stewardship forward-looking statements require a number of factors could cause management’s discussion and analysis the Company to make assumptions assumptions, actual future results and of Dishman Carbogen Amcis Limited’s 52 Social Responsibility and are subject to inherent risks and events to differ materially from those Annual Report, FY26. 58 Corporate Governance uncertainties. There is significant risk expressed in the forward- looking 2 Strategic Review Statutory Reports Financial Statements Dishman Carbogen Amcis Limited / Annual Report 2025-26 3 Global Science. Unified Execution. In a world where medicine is advancing faster than business at the early stage of the molecule lifecycle, gained traction ever, the value of a partner who can turn science as the biotech funding environment into dependable supply has never been greater. improved. Molecules in Phase III and At Dishman Carbogen Amcis Limited (imdcal), at commercial stage performed well science has always been our foundation. What at our Swiss entity, our partnership with the Japanese ADC innovator defined FY26 was the way we brought that science advanced into its second round of together: one organisation, working as one team co- investment, and our collaboration Revenue across six countries, executing with one purpose. with Celonic extended our integrated ADC offering. With 10 molecules in ₹29,319 late Phase III, 29 commercialised molecules, and a CHF 102 million new Through the year, we moved decisively This integration is what makes us product development pipeline, our from a collection of strong sites to a a one-stop solution. Development million science is progressing steadily towards single, unified platform. We formed a services are anchored in Switzerland, the market. global business development office, large- scale manufacturing in India, led by renewed leadership and brought and, from our French site, a dedicated Execution showed in our numbers as sales, finance, information technology, CDMO offering for finished parenteral well. Revenue from Operations grew EBITDA | EBITDA Margin 19.3% and business development under formulations. A customer can now 8.1% to ₹29,319 million, EBITDA rose unified global leadership across begin with the development of a 20.6% to ₹5,656 million, and EBITDA ₹5,656 Switzerland, India, France, China, the molecule and stay with us through to margin improved to 19.3%, supported United Kingdom, and the Netherlands. the finished formulation. The first API by stringent cost measures across The Carbogen Amcis sales team technology transfer agreed to by the the organisation, a revised sourcing million undertook a comprehensive visit customer from our Swiss operations to strategy that restored profitability in our to India to understand our Indian India marked a milestone on this path, Netherlands business, and a further sites’ capabilities first-hand, so that combining Swiss scientific depth with reduction in net debt. they can represent them to global Indian manufacturing scale to serve Quality remained the thread running Cash Profit | CEPS ₹27.82 customers with conviction. With key customers with greater speed and through it all. FY26 was a year in which regulatory clearances in place, we are value. our major inspections were carried out ₹4,361 selling to customers globally as one Our platforms kept moving up the and successfully passed. Our Shanghai integrated company. value curve. The SPRINT Initiative facility cleared an inspection by the (Smart and efficient, Proactive and local regulator, NMPA, our Swiss sites million agile, Regulatory compliant, Innovative cleared Swissmedic inspections, and science, No compromise on safety our Netherlands facility received its and Trusted partnership approach to renewed GMP certificate from the win more early phase projects), our Dutch authority. Profit After Tax internal programme aimed at winning Global Science. Unified ₹974.5 Execution., captures our identity. Science, pursued million across borders. Execution, delivered as one. At the centre [Showing first 8,000 characters — download PDF for full document]